Skip to main content
34°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc. Common Shares
(NY:
CYBN
)
9.530
+0.060 (+0.63%)
Official Closing Price
Updated: 8:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc. Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Strengthens Its Clinical Development Team
October 01, 2024
Via
Investor Brand Network
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
October 01, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Participate in a Panel Discussion at Upcoming Summit
September 24, 2024
Via
Investor Brand Network
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 24, 2024
From
Cybin Inc.
Via
Business Wire
CYBN Stock Earnings: Cybin Beats EPS for Q1 2024
August 09, 2024
CYBN stock results show that Cybin beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports on Status of Key Clinical Milestones
September 20, 2024
Via
Investor Brand Network
Cybin Provides Corporate Update on Upcoming Clinical Milestones
September 19, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes 38-for-1 Share Consolidation
September 19, 2024
Via
Investor Brand Network
Cybin Announces Completion of Previously Announced Share Consolidation
September 19, 2024
From
Cybin Inc.
Via
Business Wire
CYBN Stock Earnings: Cybin Beats EPS for Q4 2023
June 26, 2024
CYBN stock results show that Cybin beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Leadership Shake-Ups In Cannabis And Psychedelics: Maryland's Cannabis Chief Resigns, Costly Legal Battle In MA Drags On & More
September 06, 2024
Maryland transitioned to an adult-use cannabis market a little over a year ago. Led by the state's Cannabis Administration Director, Will Tilburg, the transition resulted in the state's legal cannabis...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
Via
Investor Brand Network
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Annual and Special Meeting of Shareholders, Share Consolidation
August 28, 2024
Via
Investor Brand Network
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
August 27, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
August 13, 2024
Via
Investor Brand Network
Exposures
Product Safety
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
August 13, 2024
From
Cybin Inc.
Via
Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases Q1 2025 Financial Results, Business Highlights
August 08, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
August 08, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in a Fireside Chat at Upcoming Conference
August 07, 2024
Via
Investor Brand Network
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Cybin Inc.
Via
Business Wire
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
July 31, 2024
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
Via
Benzinga
3 Biotech Stocks That Could Make Your Summer Unforgettable
July 30, 2024
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.
Via
InvestorPlace
Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)
July 10, 2024
Via
AB Newswire
Exposures
Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sees “Swell” of Insider Investments, Upgrade in Ranking after Positive Year-End Report
July 08, 2024
Via
Investor Brand Network
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
July 03, 2024
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.
Via
InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
July 02, 2024
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns.
Via
InvestorPlace
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
June 26, 2024
Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now!
Via
Benzinga
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
June 26, 2024
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases FY Financial Report, Business Update
June 26, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.